Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Follow-up 18F-AV-1451 PET Scan Study
NCT02051764Phase 2Terminated
- Sponsor
- Avid Radiopharmaceuticals
- Start
- May 2014
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of flortaucipir in Alzheimer's disease (AD), sponsored by Avid Radiopharmaceuticals. Primary endpoint: Change in Tau Deposition at 6 months. Started May 2014; status: terminated.
02
Drugs
flortaucipir
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02051764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02051764.